Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells

Carcinogenesis

Volumn 29, Issue 2, 2008, Pages 299-306

  Ou, Chien Chih ^a   Hsu, Shih Chung ^b,f   Hsieh, Yin Hui ^a   Tsou, Wan Ling ^a   Chuang, Tzu Chao ^c   Liu, Jah Yao ^d   Kao, Ming Ching ^a,e  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAMKANG UNIVERSITY   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f Kang Ning Junior College of Medical Care and Management   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P185; PROTEIN SERINE THREONINE KINASE; RETINOID INDUCIBLE GENE 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION;

EID: 40549137759     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm263     Document Type: Article

References (44)

1. Hobeika,A.C. et al. (1998) IFN-c induction of p21WAF1 in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int. J. Cancer, 77, 138-145.
2. Kominsky,S. et al. (2000) Down-regulation of neu/HER-2 by interferon-c in prostate cancer cells. Cancer Res., 60, 3904-3908.
3. DiSepio,D. et al. (1998) Identification and characterization of a retinoidinduced class II tumor suppressor/growth regulatory gene. Proc. Natl Acad. Sci. USA, 95, 14811-14815.
4. Huang,S.L. et al. (2000) Cloning and characterization of a novel retinoidinducible gene 1(RIG1) deriving from human gastric cancer cells. Mol. Cell Endocrinol., 159, 15-24.
5. Sers,C. et al. (2002) The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgammainduced cell death in human ovarian carcinoma cells. Oncogene, 21, 2829-2839.
6. Duvic,M. et al. (2000) Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin. Cancer Res., 6, 3249-3259.
7. Shyu,R.Y. et al. (2003) RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma. Br. J. Cancer, 89, 146-151.
8. Deucher,A. et al. (2000) The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int. J. Oncol., 17, 1195-1203.
9. Huang,S.L. et al. (2002) The retinoid-inducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res., 22, 799-804.
10. Higuchi,E. et al. (2003) Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene, 22, 4627-4635.
11. Sturniolo,M.T. et al. (2003) A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J. Biol. Chem., 28, 48066-48073.
12. Tsai,F.M. et al. (2006) RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell Signal., 18, 349-358.
13. Shih,C. et al. (1981) Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 290, 261-264.
14. Coussens,L. et al. (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139.
15. King,C.R. et al. (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science, 229, 974-976.
16. King,C.R. et al. (1989) Heterogeneous expression of erbB-2 messenger RNA in human breast cancer. Cancer Res., 49, 4185-4191.
17. Yamamoto,T. et al. (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature, 319, 230-234
18. Hung,M.C. et al. (1992) Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Lett., 61, 95-103.
19. Slamon,D.J. et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-182
20. Yarden,Y. et al. (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2, 127-137
21. Yu,D. et al. (2000) Role of erbB2 in breast cancer chemosensitivity. Bio-Essays, 22, 673-680.
22. Hynes,N.E. et al. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer, 5, 341-354
23. Kao,M.C. et al. (1998) The N-terminal 178-amino-acid domain only of the SV40 large T antigen acts as a transforming suppressor of the HER-2/neu oncogene. Oncogene, 16, 547-554.
24. Chuang,T.C. et al. (2002) The N-terminal domain of SV40 large T antigen represses the HER2-mediated transformation and metastatic potential in breast cancers. FEBS Lett., 511, 46-50.
25. Menendez,J.A. et al. (2004) Inhibition of fatty acid synthase (FAS) suppresses HER2 (erbB-2) oncogene overexpression in cancer cells. Proc. Natl Acad. Sci. USA, 101, 10715-10720.
26. Klos,K.S. et al. (2006) ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res., 15, 2028-2037.
27. Xing,X. et al. (2000) The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat. Med., 6, 189-195.
28. Ferrara,N. et al. (1997) The biology of vascular endothelial growth factor. Endocr. Rev., 18, 4-25.
29. Citri,A. et al. (2006) EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol., 7, 505-516.
30. Krzyzosiak,W.J. et al. (1992) Isolation of genes specifically expressed in flat revertant cells derived from activated ras-transformed NIH 3T3 cells by treatment with azatyrosine. Proc. Natl Acad. Sci. USA, 89, 4879-4883.
31. Roder,K. et al. (2002) Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation. J. Biol. Chem., 277, 30543-30550.
32. Jiang,S.Y. et al. (2005) Identification and characterization of the retinoic acid response elements in the human RIG1 gene promoter. Biochem. Biophys. Res. Commun., 331, 630-639.
33. Lotz,K. et al. (2005) Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. Int. J. Cancer, 116, 894-902.
34. Harris,S.L. et al. (2005) The p53 pathway: positive and negative feedback loops. Oncogene, 24, 2899-2908.
35. Gottlieb,T.M. et al. (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene, 21, 1299-1303.
36. Wang,H.Q. et al. (2005) Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene, 24, 3574-3582.
37. Longva,K.E. et al. (2005) Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer, 116, 359-367.
38. Folkman,J. (2002) Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 29, 15-18.
39. Gasparini,G. et al. (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl Cancer Inst., 89, 139-147.
40. Shaw,R.J. et al. (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 441, 421-430.
41. Sawyers,C.L. (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell, 4, 343-348.
42. Hay,N. et al. (2004) Upstream and downstream of mTOR. Genes Dev., 18, 1926-1945.
43. Drenan,R.M. et al. (2004) FKBP12-rapamycin-associated protein or mammalian target of rapamycin (FRAP/mTOR) localization in the endoplasmic reticulum and the Golgi apparatus. J. Biol. Chem., 279, 772-778.
44. Liu,X. et al. (2007) Endoplasmic reticulum and Golgi localization sequences for mammalian target of rapamycin. Mol. Biol. Cell, 18, 1073-1082.